Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Jerez De La Frontera – page 4

129 clinical trials in Jerez De La Frontera, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Jerez De La Frontera at a glance
129
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

129 trials in Jerez De La Frontera

Open in trial search

Non-small cell lung cancer

Recruiting

Study on Treating Advanced Non-Small Cell Lung Cancer with Cemiplimab and Chemotherapy Based on Blood Tumor DNA Levels

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Fundacion GECP

Study of Atezolizumab, Paclitaxel, and Carboplatin for Patients with Stage IIIA and IIIB Non-Small Cell Lung Cancer

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fundacion GECP

Neoplasm malignant

Recruiting

Study of ART6043, Olaparib, and Niraparib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ART6043
  • Sponsor:Artios Pharma Limited

Plasma cell myeloma

Recruiting

Study on Reducing Oral Side Effects of Talquetamab in Multiple Myeloma Patients Using Pregabalin, Dexamethasone, and Clonazepam

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Clonazepam
  • Sponsor:Janssen Cilag International

Small cell lung cancer

Recruiting

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer

Recruiting

Study of Sacituzumab and Zimberelimab for Patients with Resectable Non-Small Cell Lung Cancer After Surgery Without Complete Disease Clearance

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zimberelimab
  • Sponsor:Fundacion GECP

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Recruiting
Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Non-small cell lung cancer metastatic

Recruiting

Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Hormone-refractory prostate cancer

Recruiting

Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy and Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effectiveness of Moxifloxacin and Drug Combination for Treating Bone Implant Infections in Patients with Long Bone Fractures

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Squamous cell carcinoma of head and neck

Recruiting

Study on the Effects of Ficlatuzumab and Cetuximab for Adults with Recurrent or Metastatic HPV-Negative Head and Neck Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Aveo Pharmaceuticals Inc.

Bladder transitional cell carcinoma

Recruiting

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Jerez De La Frontera

What the registry says about research in the country

01 Respiratory Medicine

Clinical trials focusing on various respiratory conditions including Acute Respiratory Distress Syndrome, chronic rhinosinusitis, and asthma. Research initiatives are exploring new therapeutic approaches for both adult and pediatric patients.

  • Asthma management in children and adults
  • Nasal polyps treatment evaluation
  • ARDS therapeutic interventions

Studies include testing of novel antibodies and investigating symptom improvement in chronic conditions.

02 Oncology Research

Comprehensive studies targeting various cancer types, with particular focus on breast cancer and lung cancer. Investigations include innovative treatment combinations and targeted therapies.

  • Advanced breast cancer treatments
  • Non-small cell lung cancer therapies
  • Bladder cancer interventions

Research emphasizes personalized treatment approaches and novel drug combinations.

03 Cardiovascular Studies

Research focusing on coronary artery disease and related conditions. Studies evaluate various therapeutic approaches including antiplatelet treatments and surgical interventions.

  • Coronary artery treatments
  • Antiplatelet therapy optimization
  • Arterial dissection management

Trials aim to improve treatment outcomes and reduce complications in cardiac patients.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.